ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,937.34
-0.21%
US Tech 100
20,523.20
0.00%
다우존스 지수
43,153.13
-0.16%
Bitcoin
101,820.34
1.81%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Guardant Health Inc (GH) 시세

Guardant Health Inc

Guardant Health Inc (GH)

Gamehost Inc
37.31
0.00
(0.00%)
마감 17 1월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
37.31
매수가
36.59
매도가
37.80
거래량
-
0.00 일간 변동폭 0.00
15.81 52주 범위 39.29
market_cap
4.61B
전일 종가
37.31
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
1,933,897
발행 주식
123,554,612
배당수익률
-
주가수익률
-9.62
주당순이익(EPS)
-3.88
매출
563.95M
순이익
-479.45M

Guardant Health Inc 정보

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. 더 보기

섹터
Medical Laboratories
산업
Medical Laboratories
웹사이트
www.guardanthealth.com
본부
Dover, Delaware, USA
설립됨
-
Guardant Health Inc is listed in the Medical Laboratories sector of the 나스닥 with ticker GH. The last closing price for Guardant Health was US$37.31. Over the last year, Guardant Health shares have traded in a share price range of US$ 15.81 to US$ 39.29.

Guardant Health currently has 123,554,612 shares in issue. The market capitalisation of Guardant Health is US$4.61 billion. Guardant Health has a price to earnings ratio (PE ratio) of -9.62.

GH 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

10 시간 전
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 시간 전
Edgar (US Regulatory)

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and...

19 시간 전
Business Wire

Form 8-K - Current report

14 1월 2025
Edgar (US Regulatory)

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today...

13 1월 2025
Business Wire

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin Pilot study by National Cancer...

07 1월 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

07 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 1월 2025
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.461.2483039348736.8539.2934.8220409337.42762419CS
46.6221.570544151230.6939.2929.91191114134.60177312CS
1217.1284.794452699420.1939.2920.14193389731.60107934CS
264.2912.992125984333.0239.2920.14205792329.01597752CS
5214.2261.585101775723.0939.2915.81203923125.9665698CS
156-38.63-50.869107189975.9478.3415.81171460532.57727412CS
260-46.52-55.493260169483.83181.0715.81143471954.0532224CS

GH - Frequently Asked Questions (FAQ)

What is the current Guardant Health share price?
The current share price of Guardant Health is US$ 37.31
How many Guardant Health shares are in issue?
Guardant Health has 123,554,612 shares in issue
What is the market cap of Guardant Health?
The market capitalisation of Guardant Health is USD 4.61B
What is the 1 year trading range for Guardant Health share price?
Guardant Health has traded in the range of US$ 15.81 to US$ 39.29 during the past year
What is the PE ratio of Guardant Health?
The price to earnings ratio of Guardant Health is -9.62
What is the cash to sales ratio of Guardant Health?
The cash to sales ratio of Guardant Health is 8.18
What is the reporting currency for Guardant Health?
Guardant Health reports financial results in USD
What is the latest annual turnover for Guardant Health?
The latest annual turnover of Guardant Health is USD 563.95M
What is the latest annual profit for Guardant Health?
The latest annual profit of Guardant Health is USD -479.45M
What is the registered address of Guardant Health?
The registered address for Guardant Health is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Guardant Health website address?
The website address for Guardant Health is www.guardanthealth.com
Which industry sector does Guardant Health operate in?
Guardant Health operates in the MEDICAL LABORATORIES sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.29
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 72.30
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.13
(0.00%)
0
AACGATA Creativity Global
US$ 0.99
(0.00%)
0

GH Discussion

게시물 보기
Monksdream Monksdream 4 월 전
GH buy the dip
👍️0
Monksdream Monksdream 5 월 전
GH that awful Cathie has been a recent buyer
👍️0
x993231 x993231 6 월 전
I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.
👍️0
Monksdream Monksdream 8 월 전
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
👍️0
SubPenny0001 SubPenny0001 8 월 전
I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
👍️0
Trooperstocks Trooperstocks 8 월 전
For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 💯 1
Trooperstocks Trooperstocks 8 월 전
$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
👍️ 1 💪 1
Trooperstocks Trooperstocks 8 월 전
Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 😍 1
Trooperstocks Trooperstocks 8 월 전
$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
👍️ 1 💯 1
DewDiligence DewDiligence 2 년 전
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
👍️0
jerseyboy jerseyboy 4 년 전
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
👍️0
jerseyboy jerseyboy 4 년 전
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
👍️0
jerseyboy jerseyboy 4 년 전
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
👍️0
PR_12 PR_12 4 년 전
2-3 years I'm thinking this is @ 3-5X current share price
👍️0

최근 히스토리

NASDAQ
GH
Guardant Health
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유